The U.S. Food and Drug Administration approved Pfizer's gene therapy for hemophilia B on Friday, the second such therapy for ...

The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B.

GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents ...

Shares of Pfizer were recently down more than 35% over the past year — in part because the market’s enthusiasm for its ...

The BEQVEZ gene therapy inserts a working copy of the Factor IX (FIX) gene that codes for a high-activity FIX variant.

We expect the company to post revenue of $13.8 billion and earnings of $0.50 on a per share and adjusted basis.

Ten years after dipping its toe into the gene therapy pool in a licensing deal with Spark Therapeutics, Pfizer has gained an ...

In this match-up, Pfizer arguably stands out as the more attractive investment. The company's stock is less risky, offers a ...

Shortly after winning a stay on a COVID-19 vaccine patent lawsuit brought by Moderna, Pfizer and its German partner BioNTech ...

Pfizer (PFE) said it has received FDA approval for its one-time gene therapy Beqvez for the treatment of certain adults with ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene ...

Pfizer Inc. won U.S. approval for its first gene therapy, expanding into a promising field of medicine that has proved to be ...